New Research Reveals How Immune Systems React to Stem Cell-Derived Islet Transplants

Researchers at multiple institutions transplanted stem cell-derived islets—insulin-producing cells grown in the laboratory—into mice with human immune systems. This approach allowed scientists to observe how human immune cells respond to these grafts in a living system. The study examined both autologous grafts (made from a person's own cells) and allogeneic grafts (made from donor cells) to understand the differences in immune rejection.

Using advanced imaging technology called imaging mass cytometry, researchers identified structural differences between stem cell-derived islets and natural pancreatic islets. The lab-made islets contained a higher percentage of glucagon-producing cells (which raise blood sugar) compared to natural islets, and they also developed cysts and other cell types not typically seen in transplanted primary islets. These structural variations may influence how well these grafts function and how the immune system recognizes them.

The most striking finding was the contrast between the two types of transplants. When researchers used cells from the same individual (autologous), immune infiltration and rejection were minimal, with little to no fibrosis—scarring that can damage grafts. In contrast, donor-derived (allogeneic) islets experienced heavy immune cell infiltration, extensive cell proliferation, and pro-fibrotic processes typical of rejection.

Even when researchers introduced islet antigen-reactive T cells—immune cells that specifically target islet proteins—into mice with autologous grafts, the grafts remained largely protected from immune attack. This suggests that a person's own stem cell-derived islets may have features that prevent rejection, at least under the conditions studied.

These results point to a potential advantage of personalized medicine approaches using autologous stem cell-derived islets. However, researchers emphasize that their study had important limitations. The lab model did not successfully replicate spontaneous immune destruction of autologous grafts as would be expected in living patients with Type 1 diabetes, where the immune system naturally attacks islet cells.

The findings suggest that while autologous stem cell-derived islets may avoid rejection, scientists still need to better understand and address other challenges in creating effective treatments. More research is needed to refine these approaches and develop models that more closely mimic human immune responses to islet transplantation.

Source: JCI insight. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.